ESCRS - P036 - EFFICACY OF TOPICAL DEXAMETHASONE EYE DROPS IN PREVENTING OCULAR INFLAMMATION AND CYSTOID MACULAR EDEMA FOLLOWING UNCOMPLICATED CATARACT SURGERY WITH OR WITHOUT INJECTION OF SINGLE DOSE PERIOPERATIVE SUBTENON TRIAMCINOLONE ACETONIDE

EFFICACY OF TOPICAL DEXAMETHASONE EYE DROPS IN PREVENTING OCULAR INFLAMMATION AND CYSTOID MACULAR EDEMA FOLLOWING UNCOMPLICATED CATARACT SURGERY WITH OR WITHOUT INJECTION OF SINGLE DOSE PERIOPERATIVE SUBTENON TRIAMCINOLONE ACETONIDE

Published 2023 - 27th ESCRS Winter Meeting

Reference: P036 | Type: Presented Poster & Poster Submission | DOI: 10.82333/8jkt-f531

Authors: Enes Kesim* 1 , Bugra Karasu 2 , Ali Rıza Cenk Çelebi 3

1Department of Ophthalmology,Okan University,Istanbul,Türkiye, 2Department of Ophthalmology,Tuzla State Hospital,Istanbul,Türkiye, 3Department of Ophthalmology,Acıbadem University,Istanbul,Türkiye

Purpose

To evaluate the efficacy and safety of topical dexamethasone (DEX) eye drops in combination with a single perioperative subtenon triamcinolone acetonide (sTA) injection versus conventional topical DEX eye drops in the prevention of ocular inflammation and cystoid macular edema following cataract surgery.

Setting

Medical records of 245 eyes of 245 patients who underwent uncomplicated cataract surgery were analyzed in this retrospective controlled clinical study.

Methods

Topical DEX eye drops were administered to 128 eyes routinely post-operatively, and 117 eyes were given a single dose of sTA (40 mg/ml) together with topical DEX eye drops for postoperative care. Postoperative topical antibiotic prophylaxis was applied to all eyes. The primary outcomes were anterior chamber (AC) cells and flare, central macular thickness (CMT), best corrected visual acuity (BCVA), and intraocular pressure (IOP) measurements on day 7, day 30, day 90 and day 180 following surgery. 

Results

Although CMT increased in the DEX group, no increment was observed in the DEX + sTA treated group for all follow up periods (on day 7 (+1.3 ± 18.6 and -8.7 ± 21.9 μm, p = 0.038), on day 30  (+20.5 ± 58.4 and -4.1 ± 25.2 μm, p = 0.009), on day 90 (+7.2 ± 19.9 and -5.7 ± 30.6 μm, p = 0.029) and on day180 (+8.2 ± 22.6 and -6.4 ± 32.9 μm, p = 0.032)). There was no significant difference in terms of AC cells and flare between the two groups during the entire follow-up period (p>0.05). Significant improvement in BCVA was observed in the DEX + sTA group at day 30 (p=0.008). IOP differences were comparable, and both groups had high ocular tolerance. There were no severe adverse effects recorded.

Conclusion

Topical DEX eye drops in combination with a single dose perioperative injection of sTA have robust efficacy in preventing ocular inflammation and the development of cystoid macular edema following uncomplicated cataract surgery.